CANTON, Mass., April 25 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC:AVTI.OB) (BULLETIN BOARD: AVTI.OB) -- Avitar, Inc. ("Avitar" or the "Company") developer of the first on-site oral fluid-based screen for drugs of abuse, announced today that the Company has added nearly fifty new clients during the first six months of the current fiscal year, contributing to a significant increase in the Company's business since January, 2006. "We are gaining traction in the market as more corporations are coming to understand the value of random testing in helping to reduce the costs related to drug abuse in the workplace. The upward pressure on costs such as Workers Compensation, employee health benefit utilization, and inventory shrinkage, is due in large part to the widespread use of drugs on the job despite extensive pre-employment screening," said Peter P. Phildius, CEO. "We are focusing our sales and marketing efforts on certain market segments where workplace drug abuse levels are higher than the norm and associated costs are likewise higher. We have seen our clients generate real savings through the deployment of random drug testing and our enabling oral fluid-based testing technology." About Avitar Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen(R), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB(R), an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at http://www.avitarinc.com/. Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements. Company Contact: PR Contact: Peter Cholakis Maura Landry Avitar Inc. SHIFT Communications 781-821-2440 x117 617-681-1229 http://www.avitarinc.com/ DATASOURCE: Avitar, Inc. CONTACT: Peter Cholakis of Avitar Inc., +1-781-821-2440 ext. 117, ; or Maura Landry of SHIFT Communications, +1-617-681-1229, Web site: http://www.avitarinc.com/

Copyright